Second line of Avastin and Docetaxel beyond PD by CDDP/PEM/Ava+Ava/PEM for wild and unknown of EGFR/ ALK Non-SQ NSCLC

Second line of Avastin and Docetaxel beyond PD by CDDP/PEM/Ava+Ava/PEM for wild and unknown of EGFR/ ALK Non-SQ NSCLC - SEADOG trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009870

Enrollment

Registered

2013-01-25

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

wild and unknown of EGFR/ ALK Non-SQ NSCLC

Interventions

Avastin and Docetaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: First line 1. Non-SQ stage IIIB or IV or recurrent 2. Wild and unknown of EGFR/ ALK 3. Over age 20 years 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 5. Organ function was tolerated. Second line 6. CDDP+PEM+BEV treatment was done and judged to be PD after2 cycle of PEM+BEV maintenance at least 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 2 8. Organ function was tolerated.

Exclusion criteria

Exclusion criteria: They had a concurrent malignancy, symptomatic brain metastasis, uncontrollable complications, severe morbidity; hypersensitivity to therapeutic agents; bleeding; the possibility of being pregnant, and other conditions such as hepatic inflammation, as judged by the attending physician.

Design outcomes

Primary

Measure	Time frame
RR for Second line of Bevacizumab and Docetaxel	—

Secondary

Measure	Time frame
PFS, OS, DCR, RR forCDDP/PEM/Ava+Ava/PEM,DCR, safety	—

Countries

Japan

Contacts

Public Contactkoushi kuroda

University of Occupational and Environmental Health Second Department of Surgery

kuroda-k@med.uoeh-u.ac.jp0936917442

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026